PCSK9抑制-话题@MedSci

#PCSK9抑制#

50篇内容 | 1581人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1786841, encodeId=35e01e8684144, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, objectTitle=PCSK9抑制剂竞争白热化各大医药巨头抢占市场, objectType=article, longId=43795, objectId=a88243e95ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a88243e95ba, replyNumber=0, likeNumber=48, createdTime=2015-01-02, rootId=0, userName=wjywjy, userId=1072181, projectId=1, avatar=/img/user_icon.png, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a88243e95ba, moduleTitle=PCSK9抑制剂竞争白热化各大医药巨头抢占市场, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a88243e95ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786842, encodeId=141e1e8684282, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, objectTitle=多专家解析：降脂新药PCSK9抑制剂炙手可热, objectType=article, longId=46065, objectId=8c9946065b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c9946065b4, replyNumber=0, likeNumber=66, createdTime=2015-10-27, rootId=0, userName=wjywjy, userId=1072181, projectId=1, avatar=/img/user_icon.png, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c9946065b4, moduleTitle=多专家解析：降脂新药PCSK9抑制剂炙手可热, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c9946065b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786843, encodeId=56491e868435d, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, objectTitle=NEJM：PCSK9抑制剂Evolocumab可显著降低LDL-C水平和心血管事件（OSLER研究）, objectType=article, longId=49563, objectId=032749563aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=032749563aa, replyNumber=0, likeNumber=91, createdTime=2015-08-30, rootId=0, userName=wjywjy, userId=1072181, projectId=1, avatar=/img/user_icon.png, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=032749563aa, moduleTitle=NEJM：PCSK9抑制剂Evolocumab可显著降低LDL-C水平和心血管事件（OSLER研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=032749563aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786840, encodeId=8d0f1e86840ba, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, objectTitle=罕见病领域将成为PCSK9抑制剂实现重磅潜力的突破口, objectType=article, longId=43719, objectId=2cb743e1941, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2cb743e1941, replyNumber=0, likeNumber=65, createdTime=2015-06-02, rootId=0, userName=wjywjy, userId=1072181, projectId=1, avatar=/img/user_icon.png, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2cb743e1941, moduleTitle=罕见病领域将成为PCSK9抑制剂实现重磅潜力的突破口, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2cb743e1941)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786844, encodeId=b9201e8684475, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, objectTitle=NEJM：PCSK9抑制剂Alirocumab联合大剂量他汀可显著降低LDL-C水平, objectType=article, longId=49564, objectId=fcff495646e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcff495646e, replyNumber=0, likeNumber=69, createdTime=2015-06-21, rootId=0, userName=wjywjy, userId=1072181, projectId=1, avatar=/img/user_icon.png, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcff495646e, moduleTitle=NEJM：PCSK9抑制剂Alirocumab联合大剂量他汀可显著降低LDL-C水平, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fcff495646e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786838, encodeId=82fe1e86838b8, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, objectTitle=赛诺菲PCSK9抑制剂alirocumab 9个III期均达主要疗效终点, objectType=article, longId=38618, objectId=b1903861805, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b1903861805, replyNumber=0, likeNumber=56, createdTime=2014-09-12, rootId=0, userName=wjywjy, userId=1072181, projectId=1, avatar=/img/user_icon.png, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b1903861805, moduleTitle=赛诺菲PCSK9抑制剂alirocumab 9个III期均达主要疗效终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b1903861805)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786839, encodeId=78031e8683977, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, objectTitle=ESC 2014 ：国内外专家点评PCSK9抑制剂远期效果仍待验证, objectType=article, longId=39904, objectId=46043990410, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46043990410, replyNumber=0, likeNumber=65, createdTime=2015-04-03, rootId=0, userName=wjywjy, userId=1072181, projectId=1, avatar=/img/user_icon.png, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46043990410, moduleTitle=ESC 2014 ：国内外专家点评PCSK9抑制剂远期效果仍待验证, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46043990410)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786835, encodeId=44f71e8683594, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, objectTitle=FDA要求赛诺菲评估alirocumab认知风险 PCSK9抑制剂研发难度可能加大, objectType=article, longId=31688, objectId=117b31688b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=117b31688b0, replyNumber=0, likeNumber=76, createdTime=2014-07-10, rootId=0, userName=wjywjy, userId=1072181, projectId=1, avatar=/img/user_icon.png, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=117b31688b0, moduleTitle=FDA要求赛诺菲评估alirocumab认知风险 PCSK9抑制剂研发难度可能加大, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=117b31688b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786836, encodeId=c4ec1e8683696, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, objectTitle=安进PCSK9抑制剂evolocumab III期TESLA达主要终点, objectType=article, longId=32022, objectId=e7cc32022c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e7cc32022c7, replyNumber=0, likeNumber=55, createdTime=2014-09-16, rootId=0, userName=wjywjy, userId=1072181, projectId=1, avatar=/img/user_icon.png, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e7cc32022c7, moduleTitle=安进PCSK9抑制剂evolocumab III期TESLA达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e7cc32022c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786837, encodeId=ce0a1e868373d, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, objectTitle=ACC 2014：PCSK9抑制剂显著降低低密度脂蛋白水平, objectType=article, longId=32745, objectId=a8ae32e4548, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8ae32e4548, replyNumber=0, likeNumber=73, createdTime=2014-12-12, rootId=0, userName=wjywjy, userId=1072181, projectId=1, avatar=/img/user_icon.png, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8ae32e4548, moduleTitle=ACC 2014：PCSK9抑制剂显著降低低密度脂蛋白水平, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a8ae32e4548)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PCSK9抑制

2020-05-29

wjywjy (审核中...)

前往app查看评论内容

#PCSK9抑制#

PCSK9抑制剂竞争白热化各大医药巨头抢占市场

2015-01-02

wjywjy (审核中...)

前往app查看评论内容

#PCSK9抑制#

多专家解析：降脂新药PCSK9抑制剂炙手可热

2015-10-27

wjywjy (审核中...)

前往app查看评论内容

#PCSK9抑制#

NEJM：PCSK9抑制剂Evolocumab可显著降低LDL-C水平和心血管事件（OSLER研究）

2015-08-30

wjywjy (审核中...)

前往app查看评论内容

#PCSK9抑制#

罕见病领域将成为PCSK9抑制剂实现重磅潜力的突破口

2015-06-02

wjywjy (审核中...)

前往app查看评论内容

#PCSK9抑制#

NEJM：PCSK9抑制剂Alirocumab联合大剂量他汀可显著降低LDL-C水平

2015-06-21

wjywjy (审核中...)

前往app查看评论内容

#PCSK9抑制#

赛诺菲PCSK9抑制剂alirocumab 9个III期均达主要疗效终点

2014-09-12

wjywjy (审核中...)

前往app查看评论内容

#PCSK9抑制#

ESC 2014 ：国内外专家点评PCSK9抑制剂远期效果仍待验证

2015-04-03

wjywjy (审核中...)

前往app查看评论内容

#PCSK9抑制#

FDA要求赛诺菲评估alirocumab认知风险 PCSK9抑制剂研发难度可能加大

2014-07-10

wjywjy (审核中...)

前往app查看评论内容

#PCSK9抑制#

安进PCSK9抑制剂evolocumab III期TESLA达主要终点

2014-09-16

wjywjy (审核中...)

前往app查看评论内容

#PCSK9抑制#

ACC 2014：PCSK9抑制剂显著降低低密度脂蛋白水平

2014-12-12

科室
- - 订阅+
  - 更多科室
工具
服务